Literature DB >> 6978286

Further studies on the mitogenic and immune-modulating effects of plasminogen activator.

M A Wainberg, E Israel, R G Margolese.   

Abstract

Plasminogen activator (PA), an enzyme which is secreted in large quantities by certain types of tumour cells, is an apparent lymphocyte mitogen. Treatment of mouse spleen cells with anti-Thy-1.2 serum plus complement prevents responsiveness, indicating that T cells are being stimulated to divide. In addition to the foregoing, we have shown that PA has the capacity to interfere with certain types of cell-mediated cytotoxicity and natural killer cell reactions in which tumour cells are employed as targets. These results suggest that PA may play an immune-modulating role which may be of importance in tumour self-defense.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978286      PMCID: PMC1555426     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  12 in total

1.  Decreased production of transforming virus and altered antigenic behaviour in cultured avian sarcoma cells.

Authors:  M A Wainberg; M Yu; E Israel
Journal:  J Gen Virol       Date:  1979-02       Impact factor: 3.891

Review 2.  Synergistic effect of tumor virus transformation and tumor promoter treatment on the production of plasminogen activator by chick embryo fibroblasts.

Authors:  R H Goldfarb; J P Quigley
Journal:  Cancer Res       Date:  1978-12       Impact factor: 12.701

3.  Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue.

Authors:  L Ossowski; D Biegel; E Reich
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

4.  Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas.

Authors:  M Cikes; S Friberg; G Klein
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

5.  Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator.

Authors:  J Unkeless; K Dano; G M Kellerman; E Reich
Journal:  J Biol Chem       Date:  1974-07-10       Impact factor: 5.157

6.  Proteases as mitogens. The Effect of trypsin and pronase on mouse and human lymphocytes.

Authors:  J G Kaplan; C Bona
Journal:  Exp Cell Res       Date:  1974-10       Impact factor: 3.905

7.  Mitogenic action of trypsin and chymotrypsin.

Authors:  D Mazzei; C Novi; C Bazzi
Journal:  Lancet       Date:  1966-07-23       Impact factor: 79.321

8.  Isolation of a protease inhibitor from tissues resistant to tumor invasion.

Authors:  D B Rifkin; R M Crowe
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1977-12

9.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

10.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity.

Authors:  R B Herberman; M E Nunn; D H Lavrin
Journal:  Int J Cancer       Date:  1975-08-15       Impact factor: 7.396

View more
  5 in total

1.  Pepsin like enzyme in macrophages and its role in the immune system.

Authors:  H Ohnishi
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

2.  Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity.

Authors:  S K Sundar; J Bergeron; J Menezes
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

3.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

4.  In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.

Authors:  M S Abaza; F A Shaban; R K Narayan; M Z Atassi
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

5.  Production of plasminogen activator by human natural killer cells. Large granular lymphocytes.

Authors:  R H Goldfarb; T Timonen; R B Herberman
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.